HOXA9 and neoplasm: Previously, Malek et al. reported that suppressing HOXA9 pharmacologically avoided TWIST1-triggered invasive PCa cells in vitro and metastases in vivo, indicating that HOXA9 served as a tumor promotor in PCa [23].